Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36379345)
Watch
English
Experience with sorafenib in the treatment of advanced renal cell carcinoma.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
title
Experience with sorafenib in the treatment of advanced renal cell carcinoma
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
author
Giuseppe Procopio
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
Elena Verzoni
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
Nicola Nicolai
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
Roberto Salvioni
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
Filippo de Braud
series ordinal
6
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
author name string
Isabella Testa
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
publication date
1 December 2012
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
published in
Therapeutic advances in urology
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
volume
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
issue
6
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
page(s)
303-313
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
cites work
Treatment selection in metastatic renal cell carcinoma: expert consensus
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Second-line therapy for refractory renal-cell carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sorafenib for the management of advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Cardiotoxicity induced by tyrosine kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
EORTC-GU group expert opinion on metastatic renal cell cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sorafenib in advanced clear-cell renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
30 September 2017
Experience with sorafenib and the elderly patient
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
28 June 2018
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491759
retrieved
21 September 2018
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23205057
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23205057
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23205057
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23205057
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23205057
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1177/1756287212457216
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
PMC publication ID
3491759
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
PubMed publication ID
23205057
1 reference
stated in
Europe PubMed Central
PMC publication ID
3491759
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23205057%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
ResearchGate publication ID
233830974
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit